; or (B) whose health insurance— (i) does not cover such services; or (ii) places other barriers on the receipt of such services, such as— (I) limiting coverage of such services to a certain period of time; or (II) imposing nonquantitative treatment limitations that are more stringent than treatment limitations imposed on other medical conditions (such as a requirement to use less expensive services, like outpatient treatment, prior to more expensive, but physician-recommended services, such as inpatient or residential treatment). (5) The grant will not be used to pay or subsidize the cost of more than 60 consecutive days of opioid abuse, dependence, or addiction treatment in the case of any individual. (c) Permissible provision of medications In expanding access to clinically appropriate services for opioid abuse, dependence, or addiction through a grant under this section, a State may provide for the use of medications, in conjunction with other treatment, so long as the medications— (1) are lawfully marketed under the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq.); (2) are clinically indicated to address the abuse, dependence, or addiction; and (3) are offered consistent with consumer choice. (d) Coordination The Assistant Secretary shall coordinate the program under this section with the program for prevention and treatment of substance abuse under subpart II of part B of title XIX of the Public Health Service Act ( 42 U.S.C. 300x–21 et seq.). (e) Evaluation; dissemination of information; technical assistance (1) In general The Assistant Secretary shall— (A) require States receiving a grant under this section to report appropriate outcome measures associated with use of the grant, including any— (i) decreases in substance use; (ii) changes in retention in care; (iii) connections to the next appropriate level of care; (iv) decreases in involvement with criminal justice activities; and (v) other outcome data as appropriate